By Daniella Parra
Agendia said it has enrolled the first patient using MammaPrint for the Oncology De-Escalation of Breast Radiation (DEBRA) Trial, aiming to reduce breast radiation post-lumpectomy for low-risk, early-stage breast cancer.
The trial aims to determine whether hormonal therapy alone is as effective as the combination of standard radiation and hormonal therapy, while aiming to personalize treatment paths, Agendia said.
“I am thrilled to be offering this trial to patients with Low Risk MammaPrint because the more we learn about tumor biology, the less likely we are to overtreat women with breast cancer,” said Eric Brown, MD, FACS Breast Surgeon, Comprehensive Breast Care, A Division of Michigan Healthcare Professionals. “Ultimately, we hope that this trial will allow the 70 gene assay to determine benefit of radiation in addition to its current utilization in defining the benefit of chemotherapy and length of endocrine therapy.”
Editor@Executives-edge.com
